low-intensity venetoclax-based preconditioning followed by sequential allosct for r/r aml or hr-mds
Published 4 months ago • 89 plays • Length 2:59Download video MP4
Download video MP3
Similar videos
-
2:25
low-intensity venetoclax-based salvage as a bridge to allosct in aml
-
2:21
real-world data on venetoclax-based regimens for patients with aml or mds with excess blasts-2
-
2:19
cladribine ldac venetoclax alternated with azacitidine venetoclax in older patients with aml
-
2:45
the addition of venetoclax to hmas for the treatment of cmml: a retrospective psm analysis
-
3:09
bleximenib combined with venetoclax and azacitidine in r/r aml with kmt2a or npm1 alterations
-
9:46
venetoclax prior to allo-hct for high-risk myeloid malignancies
-
1:09
dec-c plus venetoclax in hr-mds and cmml: an analysis using different response criteria
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
58:27
laboratory nonconformance (event) management
-
11:38
flow cytometry - 2 | hematopoiesis & cd markers - in just 10 minutes !!!!
-
3:01
what is chronic myelomonocytic leukeia
-
2:12
improving the treatment of low-risk mds: luspatercept, treatment sequencing & disease classification
-
1:02
mylox-1: phase iia study of gb2064, an oral loxl-2 inhibitor in myelofibrosis
-
2:20
pevonedistat, azacitidine and venetoclax triplet therapy for aml, mds and cmml
-
2:03
the use of venetoclax in r/r al amyloidosis
-
1:03
10-day astx727 (decitabine/cedazuridine) with venetoclax in the treatment of r/r aml
-
4:26
retrospective analysis of venetoclax-based therapy in cmml
-
3:17
venetoclax with azacitidine in hr-mds
-
1:30
a phase i trial of voruciclib /- venetoclax for the treatment of nhl and aml
-
1:30
strategies for mitigating the negative impact scd has on growth and development
-
1:59
phase i study of pevonedistat, azacitidine, and venetoclax in patients with r/r aml
-
1:04
clad-ldac-ven induction therapy in aml: insights from a phase ii trial